6.
Andrew S, Titus J
. Purification of immunoglobulin G. Curr Protoc Immunol. 2008; Chapter 2:Unit 2.7.
DOI: 10.1002/0471142735.im0207s21.
View
7.
Champoux J
. DNA topoisomerases: structure, function, and mechanism. Annu Rev Biochem. 2001; 70:369-413.
DOI: 10.1146/annurev.biochem.70.1.369.
View
8.
Frese-Schaper M, Zbaeren J, Gugger M, Monestier M, Frese S
. Reversal of established lupus nephritis and prolonged survival of New Zealand black x New Zealand white mice treated with the topoisomerase I inhibitor irinotecan. J Immunol. 2010; 184(4):2175-82.
DOI: 10.4049/jimmunol.0903153.
View
9.
Barber M, Drenkard C, Falasinnu T, Hoi A, Mak A, Kow N
. Global epidemiology of systemic lupus erythematosus. Nat Rev Rheumatol. 2021; 17(9):515-532.
PMC: 8982275.
DOI: 10.1038/s41584-021-00668-1.
View
10.
Lee M, Brown S, Chen A, Hsieh T
. DNA topoisomerase I is essential in Drosophila melanogaster. Proc Natl Acad Sci U S A. 1993; 90(14):6656-60.
PMC: 46991.
DOI: 10.1073/pnas.90.14.6656.
View
11.
Furie R, Petri M, Zamani O, Cervera R, Wallace D, Tegzova D
. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011; 63(12):3918-30.
PMC: 5007058.
DOI: 10.1002/art.30613.
View
12.
Wang X, Oates J, Helke K, Gilkeson G, Zhang X
. Camptothecin and Topotecan, Inhibitors of Transcription Factor Fli-1 and Topoisomerase, Markedly Ameliorate Lupus Nephritis in (NZB × NZW)F1 Mice and Reduce the Production of Inflammatory Mediators in Human Renal Cells. Arthritis Rheumatol. 2021; 73(8):1478-1488.
PMC: 9853877.
DOI: 10.1002/art.41685.
View
13.
Lindblom J, Toro-Dominguez D, Carnero-Montoro E, Beretta L, Borghi M, Castillo J
. Distinct gene dysregulation patterns herald precision medicine potentiality in systemic lupus erythematosus. J Autoimmun. 2023; 136:103025.
DOI: 10.1016/j.jaut.2023.103025.
View
14.
Weisenburger T, von Neubeck B, Schneider A, Ebert N, Schreyer D, Acs A
. Epistatic Interactions Between Mutations of Deoxyribonuclease 1-Like 3 and the Inhibitory Fc Gamma Receptor IIB Result in Very Early and Massive Autoantibodies Against Double-Stranded DNA. Front Immunol. 2018; 9:1551.
PMC: 6041390.
DOI: 10.3389/fimmu.2018.01551.
View
15.
Rovin B, Furie R, Latinis K, Looney R, Fervenza F, Sanchez-Guerrero J
. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum. 2012; 64(4):1215-26.
DOI: 10.1002/art.34359.
View
16.
Stearns N, Pisetsky D
. The role of monogamous bivalency and Fc interactions in the binding of anti-DNA antibodies to DNA antigen. Clin Immunol. 2016; 166-167:38-47.
DOI: 10.1016/j.clim.2016.04.004.
View
17.
Contreras G, Pardo V, LeClercq B, Lenz O, Tozman E, ONan P
. Sequential therapies for proliferative lupus nephritis. N Engl J Med. 2004; 350(10):971-80.
DOI: 10.1056/NEJMoa031855.
View
18.
Morham S, Kluckman K, Voulomanos N, SMITHIES O
. Targeted disruption of the mouse topoisomerase I gene by camptothecin selection. Mol Cell Biol. 1996; 16(12):6804-9.
PMC: 231683.
DOI: 10.1128/MCB.16.12.6804.
View
19.
Huang S, Ghosh S, Pommier Y
. Topoisomerase I alone is sufficient to produce short DNA deletions and can also reverse nicks at ribonucleotide sites. J Biol Chem. 2015; 290(22):14068-76.
PMC: 4447978.
DOI: 10.1074/jbc.M115.653345.
View
20.
Khunsriraksakul C, Li Q, Markus H, Patrick M, Sauteraud R, McGuire D
. Multi-ancestry and multi-trait genome-wide association meta-analyses inform clinical risk prediction for systemic lupus erythematosus. Nat Commun. 2023; 14(1):668.
PMC: 9905560.
DOI: 10.1038/s41467-023-36306-5.
View